Cancer du sein de la femme âgée, le point de vue du chirurgien
Didier Bourgeois
Chirurgien cancérologue spécialisé en sénologie et gynécologie
à l’Institut du Sein Henri Hartmann, Neuilly Sur Seine, France
Cancer treatment is about more than just targeting tumor cells; it’s about considering the entire system, including the patient’s unique biology.
Each patient possesses a distinct metabolism and genetic makeup (polymorphism), influencing how drugs are processed, their toxicity, and effectiveness. This means that what works for one person might not work for another. We need to consider not only the molecular identity of the tumor but also the phenotypic characteristics of the host – the patient.
A crucial factor is the patient’s immune response. Some individuals have a stronger immune system capable of fighting cancer more effectively than others. This intricate interplay between tumor cells, medications, and individual immunity requires sophisticated analysis.
Traditional tools might struggle to integrate all these complex parameters. That’s where artificial intelligence (AI) comes in. By analyzing vast datasets encompassing genetic information, patient history, tumor characteristics, and immune response profiles, AI can help us define precise patient populations likely to benefit from specific treatment strategies.
This personalized approach, guided by AI, holds the potential to revolutionize cancer treatment by tailoring therapies to individual needs and maximizing effectiveness while minimizing side effects.
This article has been reviewed and edited by Dr JP Minart
Didier Bourgeois
Chirurgien cancérologue spécialisé en sénologie et gynécologie
à l’Institut du Sein Henri Hartmann, Neuilly Sur Seine, France
Joseph GLIGOROV
Oncologue, Paris, France
Copyright © 2025 - BCU
Our website uses cookies to provide you the best experience. However, by continuing to use our website, you agree to our use of cookies. For more information, read our Cookie Policy.